Why Is Diaceutics Plc Up?
Diaceutics Plc shares rose 7.06% on 22 September 2026, according to the market data, extending a recovery in sentiment following a step-change year of trading in 2025.
There is no single new company announcement dated that session, but the move follows Diaceutics' Full Year 2025 Trading Update, published in January 2026, which confirmed a return to profitability alongside strong Revenue growth.
The Company's shares have continued to attract interest as investors digest confirmation of a record order book and continued growth guidance for FY2026.
Key Highlights
Diaceutics is a technology and data solutions provider to the pharmaceutical and biotech industry, helping drug companies commercialise precision medicines through its DXRX platform.
Reported FY2025 revenue was expected at £38.5 million, representing 20% growth, with constant-currency growth of 24%, in line with analyst consensus, and adjusted EBITDA expected to exceed consensus estimates.
The Company reported a record order book of at least £36.8 million, up 48% year-on-year, and Annual Recurring Revenue of at least £20.3 million, up around 21%.
Diaceutics signed a second PMx commercialisation Partnership in Q4 2025 with a US biotech, and continues to work with 18 of the top 20 global pharmaceutical companies, with the number of customer therapeutic brands growing 12% to 95.
About Diaceutics Plc
Diaceutics is an AIM-listed technology and solutions provider focused on precision medicine diagnostics, using its DXRX data platform to help pharmaceutical companies identify candidate patients and improve commercial launch outcomes for targeted therapies.
Its customer base includes many of the world's largest pharmaceutical companies, and its revenue model combines project-based commercialisation work with a growing base of recurring, subscription-style revenue.
The Company operates from New York, Belfast and London, reflecting its close ties to both the US pharmaceutical industry and its UK listing.
Key Reasons Behind The Move
The rise appears consistent with continued investor confidence in Diaceutics' turnaround, following a multi-year value-creation programme focused on scale, profitability and recurring revenue.
Management's guidance for 25% revenue growth in FY2026, delivered alongside a record order book, gives investors visibility that the FY2025 improvement is not a one-off.
As a smaller AIM-listed healthcare technology stock, Diaceutics' share price can move meaningfully on continued evidence of Margin and revenue momentum.
Financial Position and Trading Update
Diaceutics' H1 2025 results, reported in September 2025, showed 22% revenue growth, representing a three-year compound annual growth rate of around 25%, underscoring a sustained multi-year growth trend.
The Company's FY2025 update highlighted an adjusted EBITDA margin of around 19%, representing roughly 75% year-on-year growth in adjusted EBITDA, alongside the described 'return to profitability'.
Management has attributed improving margins partly to the comprehensive deployment of AI tools across the business, supporting the transition to a higher-quality, ARR-driven commercial model.
Growth Catalysts
Continued growth in Annual Recurring Revenue, which increased 21% to at least £20.3 million, is a key catalyst as it reduces reliance on lumpier, project-based revenue.
Expansion of PMx commercialisation partnerships, including the new US biotech partnership signed in Q4 2025, broadens the Company's revenue base beyond its historic top pharma client concentration.
Growth in the number of customer therapeutic brands, up 12% to 95, and continued deepening of enterprise-wide engagements with additional top 10 global pharma customers both support the medium-term growth outlook.
Risks
Diaceutics remains reliant on a relatively concentrated base of large pharmaceutical customers, meaning the loss or delay of a major contract could have an outsized impact on results.
The Company's growth strategy depends on continued adoption of precision medicine and companion diagnostics by the pharmaceutical industry, a trend that could be affected by broader shifts in Drug Development priorities or regulation.
As with many small-cap technology and services stocks, Diaceutics' share price can be volatile around results and trading updates.
Valuation
With Diaceutics only recently returning to consistent profitability, valuation is best assessed through revenue growth, ARR expansion and order book trends rather than trailing Earnings multiples alone.
The Company's guidance for continued double-digit revenue growth into FY2026, combined with an improving margin profile, is central to the Investment case.
What Investors Should Watch Next
Investors should watch Diaceutics' full FY2025 results and subsequent trading updates for confirmation that the 25% FY2026 revenue growth guidance is being achieved.
Continued growth in ARR and the order book, along with any further PMx commercialisation partnership announcements, will be important indicators of underlying momentum.
Broader trends in pharmaceutical R&D spending and precision medicine adoption should also be monitored, given their influence on Diaceutics' addressable market.
Conclusion
Diaceutics enters 2026 on a stronger footing than in recent years, having delivered 20% revenue growth and a swing to improved profitability in FY2025, supported by a record order book.
The 7.06% rise appears consistent with growing investor confidence that this improvement can be sustained into FY2026, though the Company remains dependent on a relatively concentrated set of large pharmaceutical customers.
The key issues for LSE:DXRX will be whether the guided 25% FY2026 revenue growth materialises, whether ARR continues to expand, and whether new commercialisation partnerships broaden the customer base further.






Please wait processing your request...